Hisao Higo

452 total citations
39 papers, 211 citations indexed

About

Hisao Higo is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Hisao Higo has authored 39 papers receiving a total of 211 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Pulmonary and Respiratory Medicine, 18 papers in Oncology and 7 papers in Surgery. Recurrent topics in Hisao Higo's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (14 papers), Lung Cancer Treatments and Mutations (14 papers) and Transplantation: Methods and Outcomes (5 papers). Hisao Higo is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (14 papers), Lung Cancer Treatments and Mutations (14 papers) and Transplantation: Methods and Outcomes (5 papers). Hisao Higo collaborates with scholars based in Japan. Hisao Higo's co-authors include Katsuyuki Kiura, Yoshinobu Maeda, Katsuyuki Hotta, Go Makimoto, Kadoaki Ohashi, Eiki Ichihara, Akihiko Taniguchi, Toshio Kubo, Nobuaki Miyahara and Kiichiro Ninomiya and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Cancer Research.

In The Last Decade

Hisao Higo

34 papers receiving 209 citations

Peers

Countries citing papers authored by Hisao Higo

Since Specialization

Citations

This map shows the geographic impact of Hisao Higo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hisao Higo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hisao Higo more than expected).

Fields of papers citing papers by Hisao Higo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hisao Higo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hisao Higo. The network helps show where Hisao Higo may publish in the future.

Co-authorship network of co-authors of Hisao Higo

This figure shows the co-authorship network connecting the top 25 collaborators of Hisao Higo. A scholar is included among the top collaborators of Hisao Higo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hisao Higo. Hisao Higo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Remission of hypersensitivity pneumonitis after allogeneic hematopoietic stem cell transplantation 2024 ·Respiratory Investigation ·(unknown), Hisao Higo, (unknown), (unknown), (unknown), Toshiki Terao, (unknown), (unknown), Ken‐ichi Matsuoka, Fumiaki Tokioka, Yoshinobu Maeda, Nobuaki Miyahara	0
2	Concomitant osimertinib and antituberculosis therapy in an elderly patient with EGFR‐mutated lung cancer and pulmonary tuberculosis: A case report 2024 ·Thoracic Cancer ·Hiroaki Matsuura, Hisao Higo, (unknown), (unknown), (unknown), (unknown), Go Makimoto, Kiichiro Ninomiya, Masanori Fujii, Kammei Rai, Eiki Ichihara, Katsuyuki Hotta, Nobuaki Miyahara, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura, Kadoaki Ohashi	2
3	Pneumocystis jirovecii pneumonia mortality risk associated with preceding long-term steroid use for the underlying disease: A multicenter, retrospective cohort study 2024 ·PLoS ONE ·(unknown), Satoru Senoo, (unknown), (unknown), Goro Kimura, (unknown), Tomoki Tamura, Kenichiro Kudo, Tetsuji Kawamura, Yasuharu Nakahara, Hisao Higo, Daisuke Himeji, Nagio Takigawa, (unknown), (unknown)	1
4	Protracted coronavirus disease 2019 after chimeric antigen receptor-T cell therapy successfully treated with sequential multidrug therapy 2024 ·Respiratory Medicine Case Reports ·Masahiro Yamashita, Hisao Higo, Nobuharu Fujii, (unknown), Go Makimoto, Kiichiro Ninomiya, Masanori Fujii, Kammei Rai, Eiki Ichihara, Kadoaki Ohashi, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Nobuaki Miyahara	0
5	Pulmonary fibrosis and type-17 immunity 2023 ·Respiratory Investigation ·Satoru Senoo, Hisao Higo, Akihiko Taniguchi, Katsuyuki Kiura, Yoshinobu Maeda, Nobuaki Miyahara	11
6	Switching to Dupilumab from Other Biologics without a Treatment Interval in Patients with Severe Asthma: A Multi-Center Retrospective Study 2023 ·Journal of Clinical Medicine ·Hisao Higo, (unknown), (unknown), Yoshihiro Mori, (unknown), Akihiko Taniguchi, Satoru Senoo, Goro Kimura, Yasushi Tanimoto, (unknown), (unknown), Mikio Kataoka, Yoshinobu Maeda, Katsuyuki Kiura, Nobuaki Miyahara, (unknown)	9
7	Severe Cytokine Release Syndrome and Immune Effector Cell-associated Neurotoxicity Syndrome in a Man Receiving Immune Checkpoint Inhibitors for Lung Cancer 2023 ·Internal Medicine ·Takaaki Tanaka, (unknown), Go Makimoto, Kiichiro Ninomiya, Hisao Higo, Masanori Fujii, Eiki Ichihara, Kadoaki Ohashi, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda	4
8	Mycobacterium shinjukuense infection successfully treated with clarithromycin, rifampicin, and ethambutol 2023 ·Respiratory Medicine Case Reports ·Kayo Nakamura, (unknown), Daizo Kishino, Shuko Mashimo, (unknown), Yusaku Shibata, (unknown), Hisao Higo, Yasushi Hiramatsu, Yoshinobu Maeda, Nobuaki Miyahara	2
9	Identification of targetable kinases in idiopathic pulmonary fibrosis 2022 ·Respiratory Research ·Hisao Higo, Kadoaki Ohashi, Shuta Tomida, (unknown), Hiromasa Yamamoto, Seiichiro Sugimoto, Satoru Senoo, Go Makimoto, Kiichiro Ninomiya, (unknown), Kazuya Nishii, Akihiko Taniguchi, Toshio Kubo, Eiki Ichihara, Katsuyuki Hotta, (unknown), Yoshinobu Maeda, Shinichi Toyooka, Katsuyuki Kiura	9
10	Massive hemoptysis in a post-operative patient with recurrent lung cancer successfully treated by the combination therapy of Endobronchial Watanabe Spigot and bronchial artery embolization 2022 ·Respiratory Medicine Case Reports ·(unknown), Go Makimoto, (unknown), Kiichiro Ninomiya, Hisao Higo, Yuka Kato, Masanori Fujii, (unknown), Eiki Ichihara, Kadoaki Ohashi, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura	1
11	Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report 2022 ·SHILAP Revista de lepidopterología ·Go Makimoto, (unknown), Kadoaki Ohashi, Kiichiro Ninomiya, Hisao Higo, (unknown), Masanori Fujii, Toshio Kubo, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, (unknown), Katsuyuki Kiura	2
12	Fulminant Myocarditis for Non-small-cell Carcinoma of the Lung with Nivolumab and Ipilimumab Plus Chemotherapy 2022 ·Internal Medicine ·(unknown), Kiichiro Ninomiya, M Nakashima, Satoshi Akagi, (unknown), Hisao Higo, Katsuyuki Hotta, Yoshinobu Maeda, Hiroshi Itô, Katsuyuki Kiura	6
13	Invasion of small cell lung cancer into the limbic system from leptomeningeal metastases 2021 ·Respiratory Medicine Case Reports ·Hisao Higo, (unknown), (unknown), (unknown), (unknown), Takuya Nagata, Masako Nagayama, (unknown)	1
14	Indications for SARS-CoV-2 nucleic acid amplification test for areas with low endemicity 2021 ·Journal of Infection and Chemotherapy ·Hisao Higo, (unknown), (unknown), Takuya Nagata, (unknown)	1
15	Nintedanib can be used safely and effectively for idiopathic pulmonary fibrosis with predicted forced vital capacity ≤ 50%: A multi-center retrospective analysis 2020 ·PLoS ONE ·Satoru Senoo, (unknown), Akihiko Taniguchi, Naohiro Oda, (unknown), Hisao Higo, Naofumi Hara, Hiromi Watanabe, Hirohisa Kano, (unknown), Yasuko Fuchimoto, (unknown), (unknown), Kenichiro Kudo, Takuo Shibayama, Yasushi Tanimoto, Shoichi Kuyama, Arihiko Kanehiro, Yoshinobu Maeda, Katsuyuki Kiura, (unknown)	9
16	EGFR-TKI acquired resistance in lung cancers harboring EGFR mutations in immunocompetent C57BL/6J mice 2019 ·Lung Cancer ·Hisao Higo, Kadoaki Ohashi, Go Makimoto, Kazuya Nishii, Kenichiro Kudo, Hiroe Kayatani, Hiromi Watanabe, Hirohisa Kano, Kiichiro Ninomiya, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura	5
17	Cause of pleuroparenchymal fibroelastosis following allogeneic hematopoietic stem cell transplantation 2019 ·Respiratory Investigation ·Hisao Higo, Nobuaki Miyahara, Akihiko Taniguchi, Yoshinobu Maeda, Katsuyuki Kiura	15
18	Lung transplant candidates with idiopathic pulmonary fibrosis and long-term pirfenidone therapy: Treatment feasibility influences waitlist survival 2018 ·Respiratory Investigation ·Shin Tanaka, Kentaroh Miyoshi, Hisao Higo, Takeshi Kurosaki, Shinji Otani, Seiichiro Sugimoto, Masaomi Yamane, Katsuyuki Kiura, Shinichi Toyooka, Takahiro Oto	11
19	MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib 2018 ·Scientific Reports ·Kiichiro Ninomiya, Kadoaki Ohashi, Go Makimoto, Shuta Tomida, Hisao Higo, Hiroe Kayatani, Takashi Ninomiya, Toshio Kubo, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura	31
20	Clinical characteristics of Japanese candidates for lung transplant for interstitial lung disease and risk factors for early death while on the waiting list 2017 ·Respiratory Investigation ·Hisao Higo, Takeshi Kurosaki, Eiki Ichihara, Toshio Kubo, Kentaroh Miyoshi, Shinji Otani, Seiichiro Sugimoto, Masaomi Yamane, (unknown), Katsuyuki Kiura, Shinichiro Miyoshi, Takahiro Oto	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact